PURPOSE: To compare visual acuity (VA) change at 24âmonths in eyes with clinically significant DME (CSDME) and good VA initially treated versus initially observed in routine clinical practice. METHODS: Retrospective analysis of treatment-naïve eyes with CSDME and good VA (baseline VAââ¥â79 letters), with at least 24âmonths of follow-up and initially managed with treatment (intravitreal treatment and/or macular laser) or observation with possible treatment after 4âmonths that were tracked in a prospectively designed observational registry. RESULTS: We identified 150 eligible eyes (98 initially observed, 52 initially treated) of 130 patients. The proportion of eyes with at least a 5-letter VA loss at 24âmonths was not significantly different between the groups: 65% with initial observation and 42% with initial treatment (pâ=â0.39). However, initially observed eyes were more likely to have a 10-letter VA loss at 24âmonths (ORâ=â4.6, pâ=â0.022). Most of eyes in the initial observation group received at least one treatment (an intravitreal injection in 66% and macular laser in 20%) during the 24-month period. CONCLUSIONS: The risk of 5 letters loss was similar between both management groups. However, initially observed eyes were more at risk of developing moderate visual loss and more than 80% of them required treatment over 24âmonths.
Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry.
对于视力良好的糖尿病性黄斑水肿患者,初步观察或治疗:常规临床实践中两年结果的比较:来自对抗视网膜失明!注册的数据
阅读:9
作者:Gabrielle Pierre-Henry, Nguyen Vuong, Bhandari Sanjeeb, Mehta Hemal, Viola Francesco, Arnold Jennifer, Fraser-Bell Samantha, Barthelmes Daniel, Creuzot-Garcher Catherine, Gillies Mark
| 期刊: | Acta Ophthalmologica | 影响因子: | 2.800 |
| 时间: | 2022 | 起止号: | 2022 May;100(3):285-294 |
| doi: | 10.1111/aos.14672 | 研究方向: | 代谢 |
| 疾病类型: | 糖尿病 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
